Overview

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Arog Pharmaceuticals, Inc.
Treatments:
Crenolanib
Cytarabine
Etoposide
Etoposide phosphate
Fludarabine
Fludarabine phosphate
Idarubicin
Mitoxantrone
Vidarabine